Amneal Net Borrowings from 2010 to 2024

AMRX Stock  USD 8.35  0.10  1.21%   
Amneal Pharmaceuticals, Net Borrowings yearly trend continues to be fairly stable with very little volatility. Net Borrowings will likely drop to about 71.3 M in 2024. Net Borrowings is the difference between the amount of new debt Amneal Pharmaceuticals, Class has taken on and the amount of debt it has paid off during a given period. View All Fundamentals
 
Net Borrowings  
First Reported
2016-12-31
Previous Quarter
80 M
Current Value
20 M
Quarterly Volatility
181.1 M
 
Covid
Check Amneal Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amneal Pharmaceuticals,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 154.9 M, Interest Expense of 119.8 M or Selling General Administrative of 281.2 M, as well as many indicators such as Price To Sales Ratio of 0.42, Dividend Yield of 0.096 or PTB Ratio of 56.75. Amneal financial statements analysis is a perfect complement when working with Amneal Pharmaceuticals, Valuation or Volatility modules.
  
Check out the analysis of Amneal Pharmaceuticals, Correlation against competitors.

Latest Amneal Pharmaceuticals,'s Net Borrowings Growth Pattern

Below is the plot of the Net Borrowings of Amneal Pharmaceuticals, Class over the last few years. It is the difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period. Amneal Pharmaceuticals,'s Net Borrowings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amneal Pharmaceuticals,'s overall financial position and show how it may be relating to other accounts over time.
Net Borrowings10 Years Trend
Slightly volatile
   Net Borrowings   
       Timeline  

Amneal Net Borrowings Regression Statistics

Arithmetic Mean204,535,029
Geometric Mean125,772,971
Coefficient Of Variation68.82
Mean Deviation115,419,969
Median236,989,000
Standard Deviation140,769,315
Sample Variance19816T
Range513.3M
R-Value(0.66)
Mean Square Error12087.1T
R-Squared0.43
Significance0.01
Slope(20,727,147)
Total Sum of Squares277424T

Amneal Net Borrowings History

202471.3 M
202375 M
202283.3 M
2021-1000 K
2020175.9 M
2019-27 M
2018486.3 M

About Amneal Pharmaceuticals, Financial Statements

Amneal Pharmaceuticals, investors use historical fundamental indicators, such as Amneal Pharmaceuticals,'s Net Borrowings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Amneal Pharmaceuticals,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Borrowings75 M71.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.